Opinion

Video

Acute Lymphoblastic Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

Author(s):

Elias Jabbour, MDJames M. Foran, MD

Shared insight from key opinion leaders on clinical trial data in acute lymphoblastic leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

Related Videos
Shella Saint Fleur-Lominy, MD, PhD
Manali Kamdar, MD
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
John Burke, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ben Levy, MD, and Yan Leyfman, MD
Related Content
The FDA has approved blinatumomab (Blincyto) for the treatment of adult and pediatric patients aged 1 month or older who have CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia in the consolidation phase, irrespective of measurable residual disease status.
June 14th 2024

FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Josep-Maria Ribera MD, PhD
June 14th 2024

Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Haifa Kathrin Al-Ali, MD
June 14th 2024

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis

Ibrahim T. Aldoss, MD
June 14th 2024

CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL